+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Cancer Biological Therapy Market by Product, Route of Administration, End-Users - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6011650
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Cancer Biological Therapy Market grew from USD 64.95 billion in 2023 to USD 72.42 billion in 2024. It is expected to continue growing at a CAGR of 11.60%, reaching USD 140.04 billion by 2030.

Cancer biological therapy, also known as immunotherapy, is a treatment that uses living organisms, substances derived from organisms, or lab-produced versions of such substances to treat cancer. This field is crucial for its potential in harnessing the body’s immune system to identify and attack cancer cells while reducing damage to normal cells. Its application spans vaccines, monoclonal antibodies, and cytokines, primarily benefiting hospitals, cancer research institutes, and specialty clinics. Market growth is driven by R&D advancements, government funding, and the increasing prevalence of cancer globally. Key opportunities exist in personalized medicine developments, given the rising demand for tailored therapeutic strategies and escalating collaborations between pharmaceutical companies and biotechnology firms. However, challenges persist, including high costs associated with therapy development and potential adverse effects on patients. Moreover, regulatory hurdles and lengthy approval processes can impede market expansion. Emerging markets exhibit challenges related to healthcare infrastructure and cost management, which also impact accessibility. Notably, there is a growing opportunity in innovative technology application, such as CRISPR and CAR-T cell therapy, offering significant advancements in treatment efficacy. Addressing these challenges entails emphasizing personalized treatments and cost-effective alternatives. Continued investment in genetic and molecular research will open pathways for novel therapies and broaden their feasibility and affordability. Additionally, collaboration with academic and research institutions could enhance development pipeline efficiency and reduce associated risks. Market dynamics are characterized by rapid technological advancements and increasing competitive pressures among market players, emphasizing an imperative for continuous innovation and strategic partnerships. For meaningful growth, focus on niche markets such as pediatric oncology or rare cancers could offer specialized solutions aligning with unaddressed needs, positioning businesses to thrive in this ever-evolving landscape.

Understanding Market Dynamics in the Cancer Biological Therapy Market

The Cancer Biological Therapy Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Growing prevalence of cancer with increased healthcare expenditure
    • Increasing awareness regarding benefits of cancer biological therapy
    • Favorable government policies for cancer based therapies
  • Market Restraints
    • Capital intensive treatment
  • Market Opportunities
    • Ongoing technological advancements in cancer biologics
    • Rising research and development activities for development of efficient cancer biological therapies
  • Market Challenges
    • Probable effects of anti-cancer drug therapy

Exploring Porter’s Five Forces for the Cancer Biological Therapy Market

Porter’s Five Forces framework further strengthens the insights of the Cancer Biological Therapy Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Cancer Biological Therapy Market

External macro-environmental factors deeply influence the performance of the Cancer Biological Therapy Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Cancer Biological Therapy Market

The Cancer Biological Therapy Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Cancer Biological Therapy Market

The Cancer Biological Therapy Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Cancer Biological Therapy Market

The Cancer Biological Therapy Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Biological Therapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Biogen Inc., bluebird bio, Inc., Bristol-Myers Squibb Company, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Incyte Corp, Johnson & Johnson Services, Inc,, Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd, Pfizer Inc., Sanofi SA, Spectrum Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.

Market Segmentation & Coverage

This research report categorizes the Cancer Biological Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Product
    • Cancer Growth Blockers
    • Monoclonal Antibodies
    • Vaccines
  • Route of Administration
    • Intramuscular
    • Intravenous
    • Subcutaneous
  • End-Users
    • Hospitals
    • Specialty Centers
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of cancer with increased healthcare expenditure
5.1.1.2. Increasing awareness regarding benefits of cancer biological therapy
5.1.1.3. Favorable government policies for cancer based therapies
5.1.2. Restraints
5.1.2.1. Capital intensive treatment
5.1.3. Opportunities
5.1.3.1. Ongoing technological advancements in cancer biologics
5.1.3.2. Rising research and development activities for development of efficient cancer biological therapies
5.1.4. Challenges
5.1.4.1. Probable effects of anti-cancer drug therapy
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Cancer Biological Therapy Market, by Product
6.1. Introduction
6.2. Cancer Growth Blockers
6.3. Monoclonal Antibodies
6.4. Vaccines
7. Cancer Biological Therapy Market, by Route of Administration
7.1. Introduction
7.2. Intramuscular
7.3. Intravenous
7.4. Subcutaneous
8. Cancer Biological Therapy Market, by End-Users
8.1. Introduction
8.2. Hospitals
8.3. Specialty Centers
9. Americas Cancer Biological Therapy Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Cancer Biological Therapy Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Cancer Biological Therapy Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.4. Strategy Analysis & Recommendation
LIST OF FIGURES
FIGURE 1. CANCER BIOLOGICAL THERAPY MARKET RESEARCH PROCESS
FIGURE 2. CANCER BIOLOGICAL THERAPY MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 7. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
FIGURE 11. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. CANCER BIOLOGICAL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. CANCER BIOLOGICAL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
TABLE 1. CANCER BIOLOGICAL THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. CANCER BIOLOGICAL THERAPY MARKET DYNAMICS
TABLE 7. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CANCER GROWTH BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 22. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 23. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 25. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 27. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 28. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 29. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 30. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 31. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 32. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 33. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 38. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 42. AUSTRALIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 43. AUSTRALIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 44. AUSTRALIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 45. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 46. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 47. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 48. INDIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 49. INDIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. INDIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 51. INDONESIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 52. INDONESIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 53. INDONESIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 54. JAPAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 55. JAPAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. JAPAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 57. MALAYSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 58. MALAYSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. MALAYSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 60. PHILIPPINES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 61. PHILIPPINES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. PHILIPPINES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 63. SINGAPORE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 64. SINGAPORE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. SINGAPORE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 66. SOUTH KOREA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 67. SOUTH KOREA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. SOUTH KOREA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 69. TAIWAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 70. TAIWAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. TAIWAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 72. THAILAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 73. THAILAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. THAILAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 75. VIETNAM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 76. VIETNAM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 77. VIETNAM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 82. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 83. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 85. EGYPT CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 86. EGYPT CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. EGYPT CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 88. FINLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 89. FINLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. FINLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 91. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 92. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 94. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 95. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 97. ISRAEL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 98. ISRAEL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. ISRAEL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 100. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 101. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 103. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 104. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 106. NIGERIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. NIGERIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 109. NORWAY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 110. NORWAY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. NORWAY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 112. POLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 113. POLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. POLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 115. QATAR CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 116. QATAR CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. QATAR CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 124. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 127. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 128. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. SWEDEN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 133. SWITZERLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. SWITZERLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 136. TURKEY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 137. TURKEY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. TURKEY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 145. CANCER BIOLOGICAL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
TABLE 146. CANCER BIOLOGICAL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Cancer Biological Therapy market, which are profiled in this report, include:
  • AbbVie, Inc
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • Biogen Inc.
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Incyte Corp
  • Johnson & Johnson Services, Inc,
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd
  • Pfizer Inc.
  • Sanofi SA
  • Spectrum Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd

Methodology

Loading
LOADING...

Table Information